Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab initial treatment in polypoidal choroidal vasculopathy
ChiCTR1900021656Phase 4Completed
- Sponsor
- Ophthalmology Department of Beijing Hospital
- Start
- Jun 2016
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in polypoidal choroidal vasculopathy (PCV), sponsored by Ophthalmology Department of Beijing Hospital. Primary endpoint: Best corrected visual acuity. Started Jun 2016; status: completed.
02
Drugs
ranibizumab
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on ChiCTR1900021656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021656.